A controlled trial of phenelzine in posttraumatic stress disorder.

Thirteen patients meeting DSM-III criteria for posttraumatic stress disorder participated in a random-assignment, double-blind crossover trial comparing phenelzine (45-75 mg/day) and placebo. Ten patients completed at least 4 weeks of each treatment phase. Clinical response to phenelzine did not differ from placebo, and overall improvement by the end of the study could not be attributed to the active drug. The findings are discussed in the light of preliminary reports suggesting that phenelzine may be an effective treatment for posttraumatic stress disorder.
AuthorsM Shestatzky, D Greenberg, B Lerer
JournalPsychiatry research (Psychiatry Res) Vol. 24 Issue 2 Pg. 149-55 (May 1988) ISSN: 0165-1781 [Print] Ireland
PMID3406235 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Dexamethasone
  • Phenelzine
  • Adult
  • Anxiety (drug therapy, etiology)
  • Depression (drug therapy, etiology)
  • Dexamethasone
  • Double-Blind Method
  • Humans
  • Middle Aged
  • Phenelzine (therapeutic use)
  • Stress, Psychological (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: